On September 22, 2022 Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, reported that the abstract titled "ATRN-W1051, a novel and potent WEE1 inhibitor for the treatment of CCNE1-overexpressing ovarian cancer" will be presented at the 14th Biennial Virtual Ovarian Cancer Research Seminar Series presented by the Rivkin Center and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Aprea, SEP 22, 2022, View Source [SID1234621374]). The series will take place on September 21, 22, 28, and 29, 2022, with each day scheduled to run from 12:00-2:00pm U.S. Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"A growing body of scientific evidence provides exciting development opportunities for our WEE1 inhibitor, ATRN-W1051," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "ATRN-W1051 is designed to be a potent and selective WEE1 inhibitor with a differentiated structure and potentially preferable pharmacokinetic properties. The presented data demonstrate anti-proliferative activity against a variety of cancer cell lines and tumor growth inhibition in a genetically-defined ovarian cancer xenograft model. We look forward to completing the IND-enabling studies and plan to initiate the clinical program shortly thereafter."

A copy of the poster will be accessible from the "Events Calendar" in the News and Events section of the Aprea website.